Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Cytosine
  • Dioxolanes
  • Leukemia, Myeloid, Acute

abstract

  • Troxacitabine administered as a CIVI allows a significant increase in dose-intensity in comparison to IV bolus regimens, has antileukemic activity, and warrants additional investigation in patients with refractory AML. The recommended phase II study dose is 12.0 mg/m2 daily CIVI for 5 days.

publication date

  • January 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2006.06.6209

PubMed ID

  • 17146106

Additional Document Info

start page

  • 10

end page

  • 5

volume

  • 25

number

  • 1